A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Alzheimer’s changed the couple’s routine, but not their fight to keep going. Together, David and Pamela are awareness advocates for the Alzheimer’s Association. They’ve met with representatives on ...